FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028785220> ?p ?o ?g. }

• W2028785220 endingPage "527" @default.
• W2028785220 startingPage "524" @default.
• W2028785220 abstract "Atypical femur fractures represent a potential complication of chronic oral bisphosphonate therapy in women with osteoporosis, but the risk of atypical femur fractures among cancer patients receiving intravenous bisphosphonates at higher cumulative doses remains unclear. We examined femur fractures occurring in cancer patients treated with intravenous bisphosphonates (IVBP) to determine whether a subset may be atypical fractures. Between 2005 and 2010, we identified patients with known IVBP therapy for multiple myeloma or metastatic breast cancer, who subsequently sustained a femur fracture based on hospitalization, oncology, pharmacy and chemotherapy visit records. Radiographs were examined by an orthopedic surgeon to determine anatomic fracture site and pattern. An atypical fracture was defined as a transverse or short oblique fracture occurring below the lesser trochanter with evidence of focal hypertrophy of the lateral cortex and absence of biopsy-proven malignancy or radiation therapy at the fracture site. A total of 62 patients with breast cancer (N = 39) or multiple myeloma (N = 23) with femur fracture and prior IVBP treatment for bone malignancy were identified. There were 30 proximal hip, 18 subtrochanteric and 14 femoral shaft fractures. Intraoperative bone samples were sent in 29 of 58 fracture cases undergoing operative repair, with 76% positive for malignancy. Six cases (4 breast cancer, 2 multiple myeloma) of atypical femur fracture were identified, two with negative intraoperative pathology and four with no bone biopsy samples sent. Five of the six patients with atypical fracture had bilateral femur findings, including two with transverse fracture in the contralateral femur and three with focal hypertrophy of the contralateral cortex. Two atypical fracture cases also experienced osteonecrosis of the jaw compared to 3 in the remaining cohort (33% vs. 5%, p = 0.07). Patients with atypical fracture received more IVBP (median 55 vs. 15 doses) and zoledronic acid (32 vs. 12 doses) and had longer treatment duration (median 5.9 vs. 1.6 years) compared to patients without atypical fracture (all p ≤ 0.01). Among 62 patients who received IVBP for skeletal malignancy and experienced a femur fracture, we identified six cases of atypical fracture. While fractures in this population are often assumed to be pathologic, prospective studies investigating fracture pattern, microscopic bone pathology and pharmacologic exposures should be conducted to further examine the association of IVBP and atypical femur fractures." @default.
• W2028785220 created "2016-06-24" @default.
• W2028785220 creator A5012834102 @default.
• W2028785220 creator A5031896969 @default.
• W2028785220 creator A5034787060 @default.
• W2028785220 creator A5042903405 @default.
• W2028785220 creator A5049606658 @default.
• W2028785220 creator A5065850803 @default.
• W2028785220 creator A5087268012 @default.
• W2028785220 creator A5087962219 @default.
• W2028785220 date "2012-09-01" @default.
• W2028785220 modified "2023-10-16" @default.
• W2028785220 title "Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy" @default.
• W2028785220 cites W2002081436 @default.
• W2028785220 cites W2007494843 @default.
• W2028785220 cites W2022094899 @default.
• W2028785220 cites W2023649596 @default.
• W2028785220 cites W2044575321 @default.
• W2028785220 cites W2051516578 @default.
• W2028785220 cites W2076490579 @default.
• W2028785220 cites W2078087645 @default.
• W2028785220 cites W2100244598 @default.
• W2028785220 cites W2115856409 @default.
• W2028785220 cites W2132630382 @default.
• W2028785220 cites W2133503719 @default.
• W2028785220 cites W2137598500 @default.
• W2028785220 cites W2150954528 @default.
• W2028785220 cites W2151825217 @default.
• W2028785220 cites W2157362302 @default.
• W2028785220 cites W2165326697 @default.
• W2028785220 cites W2170309090 @default.
• W2028785220 cites W2624963411 @default.
• W2028785220 doi "https://doi.org/10.1016/j.bone.2012.05.010" @default.
• W2028785220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22634175" @default.
• W2028785220 hasPublicationYear "2012" @default.
• W2028785220 type Work @default.
• W2028785220 sameAs 2028785220 @default.
• W2028785220 citedByCount "69" @default.
• W2028785220 countsByYear W20287852202013 @default.
• W2028785220 countsByYear W20287852202014 @default.
• W2028785220 countsByYear W20287852202015 @default.
• W2028785220 countsByYear W20287852202016 @default.
• W2028785220 countsByYear W20287852202017 @default.
• W2028785220 countsByYear W20287852202018 @default.
• W2028785220 countsByYear W20287852202019 @default.
• W2028785220 countsByYear W20287852202020 @default.
• W2028785220 countsByYear W20287852202021 @default.
• W2028785220 countsByYear W20287852202022 @default.
• W2028785220 countsByYear W20287852202023 @default.
• W2028785220 crossrefType "journal-article" @default.
• W2028785220 hasAuthorship W2028785220A5012834102 @default.
• W2028785220 hasAuthorship W2028785220A5031896969 @default.
• W2028785220 hasAuthorship W2028785220A5034787060 @default.
• W2028785220 hasAuthorship W2028785220A5042903405 @default.
• W2028785220 hasAuthorship W2028785220A5049606658 @default.
• W2028785220 hasAuthorship W2028785220A5065850803 @default.
• W2028785220 hasAuthorship W2028785220A5087268012 @default.
• W2028785220 hasAuthorship W2028785220A5087962219 @default.
• W2028785220 hasConcept C121608353 @default.
• W2028785220 hasConcept C126322002 @default.
• W2028785220 hasConcept C126838900 @default.
• W2028785220 hasConcept C141071460 @default.
• W2028785220 hasConcept C2776364478 @default.
• W2028785220 hasConcept C2776541429 @default.
• W2028785220 hasConcept C2777251235 @default.
• W2028785220 hasConcept C2778195839 @default.
• W2028785220 hasConcept C2779399171 @default.
• W2028785220 hasConcept C2780554211 @default.
• W2028785220 hasConcept C2992660301 @default.
• W2028785220 hasConcept C530470458 @default.
• W2028785220 hasConcept C71924100 @default.
• W2028785220 hasConceptScore W2028785220C121608353 @default.
• W2028785220 hasConceptScore W2028785220C126322002 @default.
• W2028785220 hasConceptScore W2028785220C126838900 @default.
• W2028785220 hasConceptScore W2028785220C141071460 @default.
• W2028785220 hasConceptScore W2028785220C2776364478 @default.
• W2028785220 hasConceptScore W2028785220C2776541429 @default.
• W2028785220 hasConceptScore W2028785220C2777251235 @default.
• W2028785220 hasConceptScore W2028785220C2778195839 @default.
• W2028785220 hasConceptScore W2028785220C2779399171 @default.
• W2028785220 hasConceptScore W2028785220C2780554211 @default.
• W2028785220 hasConceptScore W2028785220C2992660301 @default.
• W2028785220 hasConceptScore W2028785220C530470458 @default.
• W2028785220 hasConceptScore W2028785220C71924100 @default.
• W2028785220 hasIssue "3" @default.
• W2028785220 hasLocation W20287852201 @default.
• W2028785220 hasLocation W20287852202 @default.
• W2028785220 hasOpenAccess W2028785220 @default.
• W2028785220 hasPrimaryLocation W20287852201 @default.
• W2028785220 hasRelatedWork W132449341 @default.
• W2028785220 hasRelatedWork W1985308509 @default.
• W2028785220 hasRelatedWork W2051350264 @default.
• W2028785220 hasRelatedWork W2375411851 @default.
• W2028785220 hasRelatedWork W2378918332 @default.
• W2028785220 hasRelatedWork W2559142728 @default.
• W2028785220 hasRelatedWork W2565055469 @default.
• W2028785220 hasRelatedWork W2595221427 @default.
• W2028785220 hasRelatedWork W3169541669 @default.

• next